GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)
A Study of Disease Progression in Genetically Defined Subjects With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
ClinicalTrials.gov Identifier: NCT03894020
Novartis Reference Number: GTSCOPE
Last Update: Feb 24, 2021
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Study Description
An observational study to evaluate the natural progression of dry AMD in genetically defined subjects
Eligibility Criteria
Inclusion Criteria:
Adults with unilateral or bilateral Geographic Atrophy (GA) due to Age-related Macular Degeneration (AMD)
BCVA of 40 letters or better using ETDRS charts
Exclusion Criteria:
Evidence or history of neovascular Age-related Macular Degeneration (AMD) or diabetic retinopathy
Significant ocular or non-ocular disease that would impact the subject's ability to participate in the study
Participation in another research study involving an investigational product within the previous 4 weeks or 5 half-lives whichever is longer from the screening/baseline OR received a gene/cell therapy at any time previously
Study Locations
Contacts
Have a question?
Call 1-888-669-6682 or email [email protected]